Community

Our community narratives are driven by numbers and valuation.

Value any stock for free in seconds

Get alerts and valuation updates

Participate in discussions

Weekly Picks

RenovoRx

Stock_Research_Today

Community Contributor

Revolutionizing Cancer Treatment

A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.

View narrative

US$4.20

74.8% undervalued

371.30%

Revenue growth p.a.

13 days ago

Apple

Investingwilly

Community Contributor

Apple: A Dying Star with an Overpriced Valuation

Intro Apple Inc. (AAPL) has long been one of the most beloved stocks in the market, celebrated for its sleek products and loyal customer base.

View narrative

US$177.34

18.9% overvalued

5.00%

Revenue growth p.a.

9 days ago

Avino Silver & Gold Mines

Agricola

Community Contributor

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Full disclosure. I am a shareholder at the time of writing this.

View narrative

CA$26.79

87.5% undervalued

78.01%

Revenue growth p.a.

13 days ago

RENK Group

Chris1

Community Contributor

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

In a renewed political landscape where a Trump administration adopts a more interventionist stance toward Ukraine, the United States sharply increases its military aid—providing advanced tank transmissions, power packs, and suspension systems. This pivot alleviates initial concerns among European allies, but it simultaneously reinforces the imperative for Europe to shore up its own defense capabilities.

View narrative

€69.87

22.2% undervalued

15.00%

Revenue growth p.a.

15 days ago

Load previous narratives

Performant Healthcare

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

Commercial Expansion And Project Turing Will Transform Operations

Key Takeaways Performant Healthcare's commercial market expansion and strategic contracts are driving future revenue growth and boosting its revenue visibility and scalability. Project Turing's technological advancements and governmental auditing opportunities are set to improve operational efficiencies, expand margins, and enhance profitability.

View narrative

US$7.00

63.1% undervalued

9.66%

Revenue growth p.a.

12 days ago

NX Filtration

AnalystConsensusTarget

Consensus Narrative from 5 Analysts

New Dutch Factory And OEM Partnerships Will Fuel Market Expansion

Key Takeaways The new factory in the Netherlands and strengthened OEM partnerships are set to significantly boost production, operational efficiency, and future revenue growth. Global sales expansion and innovative technology investments focus on water scarcity solutions, enhancing market penetration and bolstering NX Filtration's ESG reputation.

View narrative

€4.24

1.3% undervalued

68.97%

Revenue growth p.a.

12 days ago

MacroGenics

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks

Key Takeaways Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies. A robust pipeline and financial sustainability support continued R&D efforts, reinforcing prospects for growth if new treatments prove effective.

View narrative

US$5.80

72.6% undervalued

-28.74%

Revenue growth p.a.

12 days ago

Southland Holdings

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

Shands And RFK Bridge Projects Will Drive Future Progress

Key Takeaways A substantial backlog and new core projects are set to drive revenue growth and enhance margin profiles as they mature. Expansion into alternative delivery projects and infrastructure funding creates opportunities for improved revenue and margins amid a solid financial environment.

View narrative

US$4.50

20.2% undervalued

8.20%

Revenue growth p.a.

12 days ago

TTEC Holdings

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

Financial And Healthcare Markets And AI Will Expand Opportunities

Key Takeaways TTEC's expansion into diverse markets and investment in AI and offshore delivery is expected to boost revenue and net margins. Strategic hiring and focus on recurring managed services are poised to enhance revenue stability and earnings growth.

View narrative

US$5.73

7.2% undervalued

-5.44%

Revenue growth p.a.

12 days ago

MediWound

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

FDA Approval And Phase III Trial Will Expand Wound Care

Key Takeaways Strong EscharEx results and strategic partnerships boost potential sales growth, leveraging Medicare policies and Phase III trials for greater revenue prospects. NexoBrid's FDA approval and geographic expansion increase market opportunities, while new manufacturing capabilities aim to meet demand, supporting long-term revenue growth.

View narrative

US$31.00

39.8% undervalued

25.90%

Revenue growth p.a.

12 days ago

Inventiva

AnalystConsensusTarget

Consensus Narrative from 5 Analysts

Phase III Trials Will Advance Lanifibranor For MASH Treatment

Key Takeaways Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency. Key partnerships in Asia and financial strength ensure market penetration and support sustained investment, boosting future earnings potential.

View narrative

€6.30

49.3% undervalued

-0.52%

Revenue growth p.a.

12 days ago

a.k.a. Brands Holding

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

Princess Polly Expansion And Key Partnerships Will Drive Future Success

Key Takeaways Expanding Princess Polly stores and adopting a test and repeat model at Culture Kings are expected to drive revenue growth and enhance earnings. Strategic partnerships and AI investments aim to broaden market reach, improve cost efficiency, and contribute to top-line and net margin growth.

View narrative

US$23.75

63.4% undervalued

4.83%

Revenue growth p.a.

12 days ago

FuelCell Energy

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

Cost Cuts And ExxonMobil Collaboration Will Shape Our Future

Key Takeaways Strategic partnerships and collaborations in energy and hydrogen sectors are boosting revenue growth and market expansion globally, particularly in Asia and the Americas. Cost-cutting and restructuring efforts aim to enhance profitability and improve financial performance through reduced operating expenses.

View narrative

US$8.67

47.2% undervalued

25.91%

Revenue growth p.a.

12 days ago

Community

Weekly Picks

Revolutionizing Cancer Treatment

Apple: A Dying Star with an Overpriced Valuation

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

Commercial Expansion And Project Turing Will Transform Operations

New Dutch Factory And OEM Partnerships Will Fuel Market Expansion

LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks

Shands And RFK Bridge Projects Will Drive Future Progress

Financial And Healthcare Markets And AI Will Expand Opportunities

FDA Approval And Phase III Trial Will Expand Wound Care

Phase III Trials Will Advance Lanifibranor For MASH Treatment

Princess Polly Expansion And Key Partnerships Will Drive Future Success

Cost Cuts And ExxonMobil Collaboration Will Shape Our Future

Value any company in seconds

Popular companies

Community

Weekly Picks

Revolutionizing Cancer Treatment

Apple: A Dying Star with an Overpriced Valuation

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

Community Investing Ideas

Commercial Expansion And Project Turing Will Transform Operations

New Dutch Factory And OEM Partnerships Will Fuel Market Expansion

LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks

Shands And RFK Bridge Projects Will Drive Future Progress

Financial And Healthcare Markets And AI Will Expand Opportunities

FDA Approval And Phase III Trial Will Expand Wound Care

Phase III Trials Will Advance Lanifibranor For MASH Treatment

Princess Polly Expansion And Key Partnerships Will Drive Future Success

Cost Cuts And ExxonMobil Collaboration Will Shape Our Future

Value any company in seconds

Popular companies